贝前列素钠联合免疫抑制剂治疗原发性肾病综合征的疗效和安全性评价

doi:10.13481/j.1671-587x.20180631

Abstract

Abstract: Objective: To explore the clinical efficacy and safety of beraprost sodium (BPS) combined with glucocorticoid (GC) and(or) immunosuppressive agents in the treatment of the patients with primary nephrotic syndrome (PNS),and to provide evidence for its application in the treatment of PNS.Methods: Eighty-six patients diagnosed as PNS definitely were selected.They were treated with GC and(or) immunosuppressive agents and were divided into BPS group (administrated with BPS, n=42) and control group (administrated with dipyridamole or aspirin,n=44) according to their willing to the acceptance of different anti-platelet treatment regimens. The relevant laboratory indexes of the patients in two groups before and after treatment were analyzed, and the effective rate,incidence of complications and drug adverse reactions of the patients in two groups were compared.Results: Compared with control group, the urinary protein levels of the patients in BPS group at the 1st and 6th months after treatment were significantly decresed(P<0.05) and the serum albumin (ALB) levels of the patients in BPS group were significantly increased (P<0.05); the levels of fibrinogen (FIB) and D-dimer (DD) of the patients in BPS group at the 3rd, 6th and 12th months after treatment were significantly decreased (P<0.05 or P<0.01). Compared with control group, the systolic blood pressure(SBP)and diastolic blood pressure (DBP) of the patients in BPS group at the 1st month after treatment were decreased significantly (P<0.05).The cholesterol (TC) level and total effective rate of the patients in BPS group at the 6th month after treatment were higher than those in control group (P<0.05). Compared with control group, the incidence of elevation of blood pressure of the patients with normal basal blood pressure in BPS group was significantly decreased(P<0.05);the incidence of headache and dizziness was significantly increased(P<0.05).Conclusion: The safety of BPS combined with GC and(or)immunosuppressive agents in treating the PNS patients is higher and superior to the conventional antiplatelet agents.

Key words: primary nephrotic syndrome, beraprost sodium, glucocorticoid, immunosuppressive

CLC Number:

R692.6

WANG Xueting, ZHOU Guangyu, WANG Yixuan, GUO Ying, YIN Min, WU Chen. Efficacy and evaluation on safety of beraprost sodium combined with immunosuppressor in treatment of primary nephrotic syndrome[J].Journal of Jilin University(Medicine Edition), 2018, 44(06): 1291-1297.

References

[1] 王海燕.肾脏病学[M]. 3版. 北京:人民卫生出版社, 2008:269-270, 940-948.
[2] 韩世盛, 卢嫣, 王怡. 前列腺素E1治疗原发性肾病综合征的系统评价[J]. 中国中西医结合肾病杂志, 2014, 15(8):721-724.
[3] Cooper LT. Beraprost for the treatment of intermittent claudication[J]. J Am CollCardiol, 2003, 41(10):1687-1689.
[4] 中国成人肾病综合征免疫抑制治疗专家组.中国成人肾病综合征免疫抑制治疗专家共识[J]. 中华肾脏病杂志, 2014,30(6):467-474.
[5] Awsakulsutthi S, Punpho K, Mamom J, et al. Beraprost sodium for chronic diabetic foot ulcer:a randomized controlled trial in thammasat university hospital[J]. Ann Vasc Dis, 2014, 7(1):40-45.
[6] Guan J, Long L, Chen YQ, et al. Effects of beraprostsodium on renal function and inflammatory factors of rats withdiabetic nephropathy[J]. Genet Mol Res, 2014,13(2):4154-4158.
[7] Watanabe M, Nakashima H, Mochizuki S, et al. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I2 analog, beraprost sodium[J]. Am J Nephrol, 2009, 30(1):1-11.
[8] Ohba Y, Matsuyama Y, Suzuki K, et al. Beraprost improves renal function and decreases uremic toxin in renal insufficiency[J]. Nihon JinzoGakkai Shi, 2015,57:487.
[9] Takenaka, M, Iio A, Sato R, et al. A double-blind, placebo-controlled, multicenter, prospective randomized study of beraprost sodium treatment for cats with chronic kidney disease[J]. J Vet Intern Med, 2018, 32(1):236-248.
[10] Shimamura M, Miyakawa J, Doi M, et al. The pharmacokinetics of beraprost sodium following single oral administration to subjects with impaired kidney function[J]. J Clin Pharmacol, 2017, 57(4):524-535.
[11] Koyama A, Fujita T, Gejyo F, et al. Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease:a randomized, double-blind, placebo-controlled, phase Ⅱ dose finding trial[J]. BMC Nephrol, 2015, 16:165.
[12] Peng L, Li J, Xu Y, et al. The protective effect of beraprost sodium on diabetic nephropathy by inhibiting inflammation and p38 MAPK signaling pathway in high-fat diet/streptozotocin-induced diabetic rats[J]. Int J Endocrinol, 2016, 2016:1690474.
[13] Vaziri ND. Molecular mechanisms of lipid disorders in nephroticsyndrome[J]. Kidney Int, 2003, 63(5):1964-1976.
[14] Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population[J]. Circulation, 2002, 106(14):1777-1782.
[15] Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis[J]. Blood, 2003, 101(4):1243-1248.
[16] 陈怡, 万建新, 江德文, 等. 前列地尔联合贝前列素钠序贯治疗慢性肾脏病[J]. 南方医科大学学报, 2013, 33(10):1521-1524.
[17] Hiraishi H, Maeda M, Sasai T, et al. Strategy to manage low dose aspirin-induced gastrointestinal injury[J]. Nippon Rinsho, 2011, 69(2):369-375.
[18] Yamada M, Sasaki R, Sato N, et al. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model[J]. Eur J Pharmacol, 2002, 449(1/2):167-176.
[19] Nootheti S, Bielory L. Risk of cataracts and glaucoma with inhaled steroid use in children[J]. Compr Ophthalmol Update, 2006, 7(1):31-39.
[20] Goto Y, Yamaguchi S, Tamura M, et al. A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis[J]. Prostaglandins Other Lipid Mediat, 2014, 112:16-26.
[21] 鱼建平.缬沙坦联合贝前列素钠对高血压合并早期肾损伤患者肾功能、凝血功能以及内皮损伤的影响[J].海南医学院学报, 2016, 22(24):58-61.

Efficacy and evaluation on safety of beraprost sodium combined with immunosuppressor in treatment of primary nephrotic syndrome

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Metrics

Comments

Recommended 10

[1]	SI Yanfang, MO Ranran, LI Huiting, SONG Peng, LI Mingxian. AIDS complicated with adrenal insufficiency:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1030-1033.
[2]	ZHANG Yanqiu, WANG Chunsheng, WANG Kunzheng, JIANG Zhaolong. Influence of long term application glucocorticoid on expressions of HMGB1,RAGE,OPG and RANKL in bone tissue of rats [J]. Journal of Jilin University Medicine Edition, 2015, 41(05): 907-913.
[3]	HE Jing, QI Di, WANG Daoxin. Mechanism of insulin in up-regulating epithelial sodium channel α-subunit via mTORC2/SGK1 signaling pathway [J]. Journal of Jilin University Medicine Edition, 2015, 41(04): 716-720.
[4]	YANG Yan,WANG Xiao-meng,LIN Hai,LI Wei,SHI Xiu-min,SUN Jing-nan. Analysis on short-term effect of ATG combined with CsA therapy in \|severe aplastic anemia [J]. J4, 2012, 38(2): 333-336.
[5]	LI Dan\|YUAN Hai-bo\|PENG Li-ping\|HUA Shu-cheng. Classification of \|bronchial asthma based on pathological features and their responses to corticosteroid [J]. J4, 2010, 36(6): 1130-1133.
[6]	LV Xiao-Yan, WANG Chun-Yan, MENG Zhao-Jie, WANG Yun-Jing, LI Ou, CHEN Li, SHAO Ming-Bai, DU Hong-Wei. Expression of 11β-hydroxysteroid dehydrogenase 1 in skeletal muscle in rats with type 2 diabetes [J]. J4, 2010, 36(5): 875-878.
[7]	ZHAO Kai-Shu, ZHANG Yun-Feng, GUO Shi-Jie, HUANG Yan-Zhi, GAO Hang, LU Ji-Rong. Effect of interleukin-15 in pathogenesis of mouse bronchial asthma [J]. J4, 2009, 35(5): 832-836.
[8]	ZHANG Yun-Feng, DIAO Kai-Shu, ZHANG Bo, SUN Meng, LU Ji-Rong. hange of interleukin-23 level in mouse asthma model and its action mechanism [J]. J4, 2009, 35(4): 681-684.
[9]	KOU Chang-gui,LU Xiao-zhen,QI Ji,XIE Bing,YU Ya-qin. Meta-analysis on efficacy of TG and GC for nephritic syndrome [J]. J4, 2008, 34(4): 671-675.
[10]	DING Hui，WANG Jian-guo, SUN Xiao-yan，XU Li-jun. Responsibility to bronchodilatator and glucocorticosteroid in patients with bronchiectasia and reversible airflow limitation [J]. J4, 2006, 32(5): 872-875.